Please use this identifier to cite or link to this item: http://ir.swu.ac.th/jspui/handle/123456789/14107
Title: Direct renin inhibition modulates insulin resistance in caveolin-1-deficient mice
Authors: Chuengsamarn S.
Garza A.E.
Krug A.W.
Romero J.R.
Adler G.K.
Williams G.H.
Pojoga L.H.
Keywords: aliskiren
amlodipine
caveolin 1
glucose
insulin
placebo
triacylglycerol
animal cell
animal experiment
animal model
animal tissue
article
blood pressure regulation
controlled study
glucose blood level
glucose tolerance test
insulin blood level
insulin resistance
male
metabolic syndrome X
mouse
nonhuman
phenotype
priority journal
treatment duration
treatment response
triacylglycerol blood level
wild type
Amides
Animals
Antihypertensive Agents
Blood Glucose
Blood Pressure
Caveolin 1
Disease Models, Animal
Fumarates
Glucose Tolerance Test
Insulin
Insulin Resistance
Male
Metabolic Syndrome X
Mice
Mice, Knockout
Random Allocation
Renin
Triglycerides
Issue Date: 2013
Abstract: Objective: To test the hypothesis that aliskiren improves the metabolic phenotype in a genetic mouse model of the metabolic syndrome (the caveolin-1 (cav-1) knock out (KO) mouse). Materials/Methods: Eleven-week-old cav-1 KO and genetically matched wild-type (WT) mice were randomized to three treatment groups: placebo (n = 8/group), amlodipine (6 mg/kg/day, n = 18/ group), and aliskiren (50 mg/kg/day, n = 18/ group). After three weeks of treatment, all treatment groups were assessed for several measures of insulin resistance (fasting insulin and glucose, HOMA-IR, and the response to an intraperitoneal glucose tolerance test (ipGTT)) as well as for triglyceride levels and the blood pressure response to treatment. Results: Treatment with aliskiren did not affect the ipGTT response but significantly lowered the HOMA-IR and insulin levels in cav-1 KO mice. However, treatment with amlodipine significantly degraded the ipGTT response, as well as the HOMA-IR and insulin levels in the cav-1 KO mice. Aliskiren also significantly lowered triglyceride levels in the cav-1 KO but not in the WT mice. Moreover, aliskiren treatment had a significantly greater effect on blood pressure readings in the cav-1 KO vs. WT mice, and was marginally more effective than amlodipine. Conclusions: Our results support the hypothesis that aliskiren reduces insulin resistance as indicated by improved HOMA-IR in cav-1 KO mice whereas amlodipine treatment resulted in changes consistent with increased insulin resistance. In addition, aliskiren was substantially more effective in lowering blood pressure in the cav-1 KO mouse model than in WT mice and marginally more effective than amlodipine. © 2013 Elsevier Inc.
URI: https://www.scopus.com/inward/record.uri?eid=2-s2.0-84872676454&doi=10.1016%2fj.metabol.2012.07.013&partnerID=40&md5=149d7fbb327bef52ec864892f5756cd2
http://ir.swu.ac.th/jspui/handle/123456789/14107
ISSN: 260495
Appears in Collections:SCOPUS 1983-2021

Files in This Item:
There are no files associated with this item.


Items in SWU repository are protected by copyright, with all rights reserved, unless otherwise indicated.